TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7784339
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release acetaminophen (paracetamol) tablet A
Study: 9043840
Drug: Antianginal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal therapy (nitrates and calcium antagonists)
Study: 18486739
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg
Study: 11903465
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) administered at 18 mg/kg as an intravenous intraoperative load, followed by daily doses to maintain serum PHT concentrations within the 10-20 aeg/ml range for 7 days.
Study: 11903465
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PHT administered).
Study: 9532988
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg controlled‐release aspirin
Study: 21209397
Drug: Sulindac 150
Normalized name: sulindac 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 150 mg bid
Study: 19335924
Drug: Daidzein (DAI)
DrugBank: Daidzein (DB13182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daidzein (DAI) and daidzein-7-O-beta-D-glucoside (DG) (1 mg DAI aglycone equivalents/kg body weight)
Study: 17768180
Drug: 10 billion
Normalized name: CVS Probiotic 10 Billion Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 billion heat-killed L. acidophilus LB plus 160 mg of spent culture medium
Study: 11837149
Drug: Propofol groups
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol groups (both doses)
Study: 19608566
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin during IVF and first trimester of pregnancy
Study: 3136831
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg recombinant tissue plasminogen activator
Study: 3136831
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg recombinant tissue plasminogen activator
Study: 3136831
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg recombinant tissue plasminogen activator
Study: 26234442
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (Levemir) and biphasic insulin (NovoMix70)
Study: 15808033
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of quinine treatment
Study: 30924071
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral medication
Study: 27555198
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg morphine + 75 μg clonidine
Study: 22556178
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and 1 mg citric acid
Study: 12975186
Drug: Cold gel
Normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold gel (Ice Power)
Study: 1640004
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg administered twice on day 8
Study: 26232942
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of cardiosphere-derived cells (CDCs)
Study: 8916626
Drug: therapy
Normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: therapy
Study: 17940609
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine (5, 20, and 80 microg doses)
Study: 17940609
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine (80 microg dose)
Study: 17940609
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine
Study: 17940609
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Hepatitis B vaccine - Recombivax)
Study: 8922515
Drug: Chemically cured
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemically cured adhesive (Lee Insta‐bond, Lee Pharmaceuticals, EI Monte, Calif.)
Study: 25001954
Drug: Cortisol (CRT)
Normalized name: Corticool
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortisol (CRT) 40 mg
Study: 23085738
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg loading dose (LD) followed by 7.5 mg maintenance dose (MD) for 10 days
Study: 23085738
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg loading dose (LD) followed by 5 mg maintenance dose (MD) for 10 days
Study: 28501668
Drug: fluoroquinolone monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoroquinolone monotherapy
Study: 8147243
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (group 2)
Study: 3539613
Drug: Isosorbide-5-mononitrate (5-ISMN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (5-ISMN) 60 mg in a controlled release formulation (Durules) given once daily
Study: 31248918
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin (300‐2700 mg)
Study: 19834330
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Control group)
Study: 8646821
Drug: Intravenous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol (0.3 gm/kg)
Study: 15292333
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH (1.7 microg/kg.d)
Study: 19663688
Drug: Liquid diclofenac
Normalized name: diclofenac Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid diclofenac formulation (1 mL, 25 mg)
Study: 16604967
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of saline solution with 100 ml of contrast material (300 mgI/ml)
Study: 19639462
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (520 mg once a day)
Study: 335789
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 400 mg per day
Study: 18221460
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (0.25 mg twice daily for 6 weeks, then half dose for another 6 weeks)
Study: 1348805
Drug: Injection treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection treatment (1‐2 ml of 1 in 10,000 adrenaline injected at four to six sites around the ulcer)
Study: 8227938
Drug: Spray to
Normalized name: DERMUSPRAY TOP AEROSOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray to eyes that were closed
Study: 21973111
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment group
Study: 15370633
Drug: Fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated milk (250 mL, 5 ppm F)
Study: 19644125
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for complex targets
Study: 12623986
Drug: Cyclosporine therapy
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine therapy
Study: 11970744
Drug: Exemestane (EXE)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane (EXE) 25 mg once daily (n=366)
Study: 7723663
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment for 2 years (Group 1)
Study: 30262574
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment in addition to standard of care)
Study: 10821460
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin replacement therapy
Study: 10978944
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg loperamide
Study: 1447035
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (chemotherapy (5‐FU/FAM) alone, radiation therapy alone, or chemotherapy+radiation therapy)
Study: 17608947
Drug: Emergency surgery
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency surgery (current standard treatment)
Study: 1797522
Drug: Motivation programme
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivation programme (individual and group basis with client-centred and cognitive-behavioural therapy approaches)
Study: 6420832
Drug: Chlorimipramine (CI)
Normalized name: Chlorimipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorimipramine (CI) 25 mg
Study: 22759333
Drug: Lansoprazole with
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole with amoxicillin and clarithromycin (LAC)
Study: 19171708
Drug: IFN-alpha-2a 9
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha-2a 9 million U three times weekly
Study: 8787880
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g over 24 h continuous infusion (CI)
Study: 11568071
Drug: Endovascular graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular graft (EVG) treatment
Study: 17159824
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (0.05 mg daily)
Study: 15897165
Drug: Calcipotriol solution
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol solution 0.005%
Study: 15055895
Drug: 14-G cannula
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14-G cannula with local anaesthesia
Study: 3396547
Drug: Suxamethonium administration
Normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suxamethonium administration
Study: 16267659
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75 mg daily)
Study: 2372037
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing 30 to 50 micrograms of ethinyl estradiol
Study: 9401083
Drug: First CR
Normalized name: Acetaminophen/Pamabrom 325 MG-25 MG Oral Tablet [MEDI-FIRST CRAMP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First CR duration >= 12 months and WBC count at relapse < 20 x 10(9)/l
Study: 7525055
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) at a maximum tolerated dose of 1000 mg/m2, administered at 14-day intervals, supported by peripheral blood progenitors and filgrastim.
Study: 7525055
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) at various dose levels: Level I (500 mg/m2), Level II (800 mg/m2), Level III (1200 mg/m2), Level IIIa (1000 mg/m2), and Level IV (1000 mg/m2) plus cyclophosphamide (CPA) at 1500 mg/m2.
Study: 7525055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBDCA (1000 mg/m2) plus CPA (1500 mg/m2) in Level IV.
Study: 12686335
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg/day
Study: 12685617
Drug: Chronic nitrate
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic nitrate treatment for 6 months after MI
Study: 23569308
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus zibotentan 10 mg/d
Study: 11396760
Drug: Sclerotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy with a 3% ethanolamine oleate solution (group 1, 18 patients)
Study: 16154241
Drug: Subcutaneous measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous measles vaccine (10(4.28) CCID50/0.5 mL)
Study: 24267258
Drug: High potency
Normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High potency statins and combined therapy
Study: 19454639
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (CBT plus zolpidem) followed by CBT alone
Study: 12217810
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose anti-thymocyte globulin (ATG) early treatment group
Study: 668784
Drug: Oral chlordiazepoxide
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chlordiazepoxide hydrochloride (100 mg)
Study: 10088935
Drug: Inhaled carbachol
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled carbachol
Study: 24192015
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (300 mg/day)
Study: 10672218
Drug: Continuous retraction
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous retraction force averaging 18 g
Study: 10672218
Drug: Continuous retraction
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous retraction force averaging 60 g
Study: 29850244
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day
Study: 6850464
Drug: BCG administered
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG administered orally in nonrandomized studies of patients with malignant melanoma and stage IV breast carcinoma
Study: 8573687
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg oral dose of terbinafine
Study: 15234136
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin applied 1 hour before surgery (control group)
Study: 31334544
Drug: LD +
Normalized name: Children's Tylenol Cold + Flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD + MCT group (1.2 g l-leucine, 20 μg cholecalciferol, 6 g/d MCTs)
Study: 23475103
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) pre-treatment for 4 days prior to chemotherapy
Study: 2850807
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (15-30 g per day)
Study: 15968231
Drug: Long-term family
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term family therapy (20 sessions over 12 months)
Study: 26670630
Drug: Half-dose photodynamic
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose photodynamic therapy (PDT)
Study: 24366433
Drug: Sterile 0.9%
Normalized name: Sodium Chloride;Vancomycin Hydrochloride;Water, Sterile 0.9%; 1 GM Intravenous Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 0.9% sodium chloride solution (control)
Study: 14558957
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (5-8 times daily)
Study: 14558957
Drug: Dobell's solution
Normalized name: Dobell's Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobell's solution (5-8 times daily)
Study: 10999838
Drug: GH receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH receptor antagonist (B2036)
Study: 8448068
Drug: Isradipine sustained
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine sustained release (I-SRO) 5 mg AM
Study: 29705650
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (BAT)
Study: 829223
Drug: Local thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Local thiotepa chemotherapy after TUR
Study: 21338187
Drug: Weekly GCSF
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly GCSF therapy before weekly craniospinal radiotherapy
Study: 7878390
Drug: Desmopressin spray
Normalized name: desmopressin Nasal Spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin spray
Study: 21592879
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Amlodipine/valsartan)
Study: 31402718
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) 400 mg
Study: 22408266
Drug: Discontinued antidepressant
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued antidepressant treatment (63 patients)
Study: 3033444
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (EV) 2 mg/day for 21 days + NET
Study: 3033444
Drug: Oestriol (E3)
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol (E3) 2‐4 mg/day
Study: 6349744
Drug: Radical radiotherapy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiotherapy followed by chemotherapy using doxorubicin (Adriamycin) and 5-fluorouracil
Study: 22159966
Drug: Topical Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Mitomycin C
Study: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
Normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-hydroxy-camptothecin (10-HCPT) 4 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Study: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
Normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-hydroxy-camptothecin (10-HCPT) 6 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Study: 26521571
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of acupuncture at head points and seed-pressure at ear points
Study: 8613890
Drug: Wheat fiber-supplemented
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat fiber-supplemented diet (40 g dietary fiber)
Study: 26002049
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg/day
Study: 19834314
Drug: Polyphenol-rich antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich antioxidant supplement containing pomegranate extract, green tea extract, and ascorbic acid
Study: 16363622
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 18FDG-PET and bone scintigraphy
Study: 12398236
Drug: Post-breakfast C-peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-breakfast C-peptide levels <= 0.8 nmol/l
Study: 9884259
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg q.i.d.)
Study: 9884259
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg t.i.d.)
Study: 9884259
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir vs. ganciclovir in D+R- patients